Current Research Studies

A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) plus VINO-CPO Maintenance in Patients with High Risk Rhabdomyosarcoma (HR-RMS)


What is the goal of the study?

Patients with high-risk rhabdomyosarcoma (HR-RMS) continue to have poor outcomes with 3-year event free survival (EFS) rates of 30% or less despite dose intensification on the most recent cooperative group RMS trials. Vinorelbine (VINO) has demonstrated clinical activity in RMS patients with relapsed and refractory disease and has been shown to provide a survival benefit when given as maintenance chemotherapy along with oral cyclophosphamide for a select group of patients who have achieved a complete remission.

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team: